ABOUT US

We strive to make a complicated
procedure simple.

About Vytronus

Vytronus, Inc. was formed in 2006 to harness the imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. We recognize that today’s marketed technologies have limitations. Only a new energy source, such as collimated ultrasound, can shift the treatment paradigm to more predictable outcomes. We strive to make a complicated procedure simple. Ease of use guides every aspect of our design philosophy. At Vytronus, patient safety is always our first priority and improved efficacy is our mission. We look forward to making our products available to doctors and their patients in the near future.

We are passionate about transforming the way atrial fibrillation is treated.

Leadership

  • John Pavlidis

    CEO

    John joined Vytronus in 2015 as the President and Chief Executive Officer. John has more than twenty-five years of medical device experience, including more than fifteen years as Chief Executive Officer of large and small organizations. Prior to Vytronus, John was President and Chief Executive Officer of Endoscopic Technologies, Inc. a leader in minimally invasive and endoscopic cardiac ablation, valve repair or replacement, and coronary bypass surgical technology. Endoscopic Technologies was acquired by AtriCure in late 2013. Previously, John served as President and Chief Executive Officer of R2 Technology Inc., the pioneer and leader in computer-aided detection of breast cancer and lung abnormalities, until Hologic Inc. acquired the company in 2006. Before joining R2 Technology, John was the President of the Ultrasound group at Siemens Healthcare for five years, where he led the acquisition and integration of Acuson Inc. and subsequent growth to $1 Billion in revenue. John earned a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and an M.S. in Engineering Sciences from the Thayer School of Engineering at Dartmouth College.

  • Patrick Phillips, PhD

    Sr. VP Engineering & Manufacturing

    Patrick joined Vytronus in 2009 and serves as Senior Vice President of Engineering and Manufacturing. Patrick has over eighteen years of experience in developing medical products including minimally invasive imaging devices and catheter-based devices for improving cardiovascular care. Patrick has worked as an independent consultant and held management positions for both large and small medical device companies. Prior to Vytronus, Patrick led the Engineering department at Fluid Medical as the Director of Engineering and held the positions of Technical Fellow and Sr. Engineering Manager at Acuson and Siemens Medical Solutions, where he developed and invented novel solutions for high-end ultrasound-based imaging systems. Patrick holds thirty-four medical device patents. Patrick earned a B.S. Electrical and Computer Engineering from Clarkson University and a Ph.D. in Biomedical Engineering from Duke University.

  • Danielo Piazza

    VP Software Engineering

    Danielo joined Vytronus in 2011 and serves as the Vice President of Software Engineering. Danielo has more than twenty-five years of experience developing software for medical devices in diagnostic imaging and robotic-guided therapy. Prior to Vytronus, Danielo was Senior Director of Systems and Software at Hansen Medical, Inc., a pioneer in robotic catheter cardiac ablation systems. Previously, Danielo led the Systems Software team and led new product initiatives at Carl Zeiss Meditec, Inc. He also served as Engineering Manager at Acuson, responsible for automated measurement systems for ultrasound imaging transducers. Danielo earned a B.S. in Electronic Engineering from Cal Poly, San Luis Obispo and an M.S. in Software Engineering from Santa Clara University.

  • Francis Macnamara

    VP Catheters & Disposables

    Francis joined Vytronus in 2016 and serves as the Vice President of Catheters and Disposables. Francis has over 19 years of experience in Research and Development in the medical device industry. Prior to Vytronus, Francis was Vice President of R&D at Hansen Medical, Inc., a pioneer in robotic catheter cardiac ablation systems. He spent the first 10 years of his career with Boston Scientific designing cardio vascular stent systems and steerable endoscopes. He is an inventor on twenty-two issued and pending patents involving catheter and robotic technologies. Francis holds a B.S. in Mechanical Engineering from the University of Limerick, Ireland, and an MBA from Santa Clara University.

  • Andra Thomas

    VP Clinical & Regulatory Affairs

    Andra (Andi) joined Vytronus in 2018 and serves as the Vice President of Clinical and Regulatory Affairs. Andi has over 30 years of experience in managing complex clinical and medical affairs across many different medical disciplines. She has served for over a decade as Vice President of Clinical Affairs at St. Jude CRM Division and held other Clinical leadership roles at Celonova, CytoPheryx, Cambridge Heart and Guidant. Andi was also involved with the development and FDA approval of the first implantable cardiac defibrillator system (Intec Systems) and early stage development of Cardiac Resynchronization Therapy device systems for the treatment of heart failure (Guidant). Andi attended the Barnes Hospital School of Nursing, John Hopkins University and College of Notre Dame.

  • Dave White

    VP Manufacturing

    Dave joined Vytronus in 2012 as Vice President of Manufacturing. David has over twenty years of medical device experience. Prior to Vytronus, Dave has held executive management and engineering positions in both R&D and Operations at companies within the medical device industry including Promed, EndoTex Interventional Systems, Cardiovascular Imaging Systems, and Advanced Cardiovascular Systems. Dave holds thirty-three U.S. patents in a variety of technologies including catheter, ultrasound, and orthopedic devices. Dave earned a B.S. in Mechanical Engineering from San Francisco State University.

  • Paul Chan

    VP Finance & Administration

    Paul joined Vytronus in 2015 and serves as the Vice President of Finance. He has over fifteen years of experience serving in various financial management and corporate development functions with small and medium-sized medical device companies. Prior to Vytronus, Paul was the consulting CFO of Endosee Corp. which introduced the first single-use CMOS hysteroscope for diagnostic hysteroscopy. Endosee was acquired by Cooper Surgical in 2014. He has also served in various capacities with QView Medical (Computer-Aided Detection of breast cancer in ultrasound images), O2 MedTech (NIR Spectroscopy for cerebral and tissue monitoring), Endoscopic Technologies Inc. (minimally invasive and endoscopic cardiac ablation) and R2 Technology Inc. (pioneer and leader in Computer-Aided Detection of breast cancer and lung abnormalities). Paul earned a B.A. in Economics and M.S. in Industrial Engineering from Stanford University.

  • John Dovala

    Snr. Director Hardware Engineering

    John joined Vytronus in 2014 and has thirty years of medical device experience. Prior to Vytronus, John has held leadership positions in both Engineering and Operations at companies within the medical device industry including Acuson, Hansen Medical, and Intuitive Surgical. John earned a B.S. in Electrical Engineering from University of the Pacific and an MBA from Santa Clara University.

  • David Harari

    Snr. Director Clinical Affairs

    David joined Vytronus in 2015. He has led successful clinical programs at numerous medical device companies, most recently at Endosense where contact force sensing for ablation was first developed, then acquired by St. Jude Medical, now Abbott. Prior to joining Vytronus, he managed clinical and engineering teams at large and small companies over a thirty year career including Intermedics, Guidant, Boston Scientific and Electro-Catheter Corp., one of the first EP businesses in the US. David trained as a biomedical engineer at the University of Michigan and devoted 7 years to clinical research at Newark Beth Israel Medical Center in EP and implantable devices.

Board of Directors

  • David McIntyre

    ATP

    David McIntyre has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.
    More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare’s global commercialization phase for the period from 2008 through 2011.
    Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.
    David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia)

  • Hank Kucheman

    BioStar Ventures

    Hank was appointed to the Vytronus board of directors in 2014 as a representative of BioStar Ventures. Hank serves as a Director of BioStar, which includes representing the firm as a Senior Advisor or Board Member to various BioStar portfolio companies. He also is a member of the Board of Directors of Hill Rom, Inc., Element Science, and Corpak Medical. Hank previously served as Chief Executive Officer for Boston Scientific. Before being named CEO in October 2011, Hank was Executive Vice President and President of the Cardiology, Rhythm, and Vascular (CRV) Group and was responsible for the Company’s Interventional Cardiology and Cardiac Rhythm Management businesses and its Endovascular Unit, which includes the Peripheral Interventions, Neurovascular, Imaging, and Electrophysiology businesses. Both within and before joining Boston Scientific, Hank held a variety of management positions in sales and marketing for SCIMED, Charter Medical Corporation, and Control Data Corporation. Hank began his career at the United States Air Force Academy Hospital and later was Healthcare Planner, Office of the Surgeon General, for the United States Air Force Medical Service. Hank earned a B.S. and M.B.A. from Virginia Polytechnic Institute and State University. Hank has served on several industry boards, including the Board of Directors of the Global Health Exchange.

  • Ross Jaffe, MD

    New Enterprise Associates

    Ross Jaffe, MD is an experienced healthcare venture capitalist with particular expertise in medical technology.  Dr. Jaffe is one of the founding Managing Directors of Versant Ventures, a healthcare-focused venture capital firm, where for the last twenty years he has focused primarily on early-stage medical device companies. Having retired from active investing for Versant in 2016, he now serves as a Venture Advisor to New Enterprise Associates (NEA) while completing his Versant responsibilities.  Prior to founding Versant, Dr. Jaffe was a General Partner at Brentwood Venture Capital, where he led investments in medical device, drug delivery, biotechnology, healthcare services, and healthcare information system companies.

    Dr. Jaffe has served on the boards of multiple successful medical technology companies, including Acclarent, St. Francis Medical Technologies, Therasense, Insulet, Novacept, and Ablation Frontiers. He currently represents Versant on the boards of AlterG and Minerva Surgical, and represents NEA on the boards of Fire1, Relievant, Vertiflex, and VytronUS. He is also a director of DocMatter.  Dr. Jaffe earned a BA in Policy Studies from Dartmouth; an MD from the Johns Hopkins School of Medicine; and an MBA from the Stanford Graduate School of Business.  He completed his residency in internal medicine and served as part-time attending physician at the University of California, San Francisco.

    Dr. Jaffe has played an active role in the venture capital and medical device communities, including serving as a Director of the National Venture Capital Association (NVCA), the Western Association of Venture Capitalists, and the Medical Device Innovation Consortium (MDIC), an FDA-industry public-private partnership focused on improving regulatory science regarding medical technology.  Dr. Jaffe was honored with the NVCA Outstanding Service Award in 2017 and has been recognized on the Forbes Midas List of leading venture capitalists in 2008, 2011, and 2012.  Dr. Jaffe is a current member and former Chair of the Board of Advisors of the Geisel School of Medicine at Dartmouth, and a former Chair of the Board of the Children’s Health Council in Palo Alto, CA.

  • Roy Tanaka

    Independent

    Roy was appointed to the Vytronus Board of Directors in 2010. He is currently a member of the Boards of Directors of Coherex, Advanced Cardiac Therapeutics, and BioSig Technologies and has served on the boards of Volcano and Tomotherapy. From 2004 through 2008, Roy served as the Worldwide President of Biosense Webster, Inc. for Johnson & Johnson. Roy joined Johnson & Johnson as the U.S. President of Biosense Webster, Inc. in 1997. From 1992 through 1997, Roy served in a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer. From 1989 to 1992, Roy served in Vice President roles with Shiley, a division of Pfizer Inc. Roy earned a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.

  • John Pavlidis

    CEO

    John joined Vytronus in 2015 as the President and Chief Executive Officer. John has more than twenty-five years of medical device experience, including more than fifteen years as Chief Executive Officer of large and small organizations. Prior to Vytronus, John was President and Chief Executive Officer of Endoscopic Technologies, Inc. a leader in minimally invasive and endoscopic cardiac ablation, valve repair or replacement, and coronary bypass surgical technology. Endoscopic Technologies was acquired by AtriCure in late 2013. Previously, John served as President and Chief Executive Officer of R2 Technology Inc., the pioneer and leader in computer-aided detection of breast cancer and lung abnormalities, until Hologic Inc. acquired the company in 2006. Before joining R2 Technology, John was the President of the Ultrasound group at Siemens Healthcare for five years, where he led the acquisition and integration of Acuson Inc. and subsequent growth to $1 Billion in revenue. John earned a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and an M.S. in Engineering Sciences from the Thayer School of Engineering at Dartmouth College.

Investors